Life Sciences Underwriter Appetite
Appetite is dynamic. The useful insight is why a market quoted, referred or declined - not a permanent green or red label on any insurer or product category.
Specialist
Market access
Hard-to-place
Our focus
Australia
National broking
Recognition
The Tank take
Life sciences appetite varies by insurer, product, end use, regulatory stage, country, limit and the quality of the submission. Every observation below is dated placement experience, not a permanent market rule.
Defined consulting and clinical-research risks tend to have clearer placement pathways. Peptides, livestock end uses, battery-powered consumer devices, high PI limits and USA exposure tend to require deeper referral, more evidence or alternative structures. All of it moves with capacity, claims and market conditions.
The appetite patterns from Tank's placements
Recurring signals from real life sciences placements. Each one is an observation from specific submissions, not a whole-of-market promise.
Consultant submissions with explicit negative statements - no products, no patients, no trials, no regulatory sign-off - have repeatedly supported placements that broad occupation labels could not. Ambiguity is priced; clarity is quoted.
Testing, traceability, supplier insurance and enforceable rights of recourse have repeatedly improved product submissions. On one battery-powered consumer device, batch testing and recourse conditions were the difference between a quote and no quote.
Livestock applications, emerging peptide categories and button-battery consumer products have each narrowed appetite in recent placements, independent of the quality of the underlying business.
$5M and $10M PI requests can trigger referral even for small consultancies, and underwriters ask why the limit is needed. A signed contract answers the question; a preference does not. US jurisdiction adds contract-level review and material premium change.
A specialist market can be technically willing to write a risk while its minimum premium is disproportionate for a small start-up - we have seen a minimum around $10,000 against very modest revenue. Placement route matters as much as appetite.
The negative statements that sharpen a submission
Where they are true, these statements have been unusually effective at helping underwriters classify life sciences risks. Answering in this form improves the quality of the whole conversation.
- 01
Does not sponsor or conduct clinical trials
- 02
Does not provide patient care or clinical advice
- 03
Does not manufacture, import, distribute or sell products
- 04
Does not act as study director or sponsor representative
- 05
Does not approve, sign or submit study results or regulatory filings
- 06
Does not handle samples or attend laboratories
- 07
Does not diagnose, prescribe or recommend treatment
- 08
Software is a memory aid, not a clinical-decision tool
- 09
No USA exposure is required
- 10
Professional or clinical practice is insured separately
Only ever state what is actually true - these are disclosure statements, not magic words. Where one does not hold, the exposure it describes needs to be declared and structured instead.
How to read an appetite signal
When a market declines or refers a life sciences risk, the reason matters more than the outcome. Activity, product, end use, geography, limit and minimum premium each point to a different next move: sometimes a different market, sometimes a different structure, sometimes better evidence in the same submission.
One decline does not mean every insurer will decline - it may reflect that market's appetite or the way the risk was presented. Equally, some risks remain commercially impractical to insure at a given moment, and knowing that early is worth more than a season of optimistic submissions.
If your risk has been declined or you are staring down a renewal in one of the harder categories, talk to us - the fastest way to test current appetite is a precise submission to the right markets.
Related life sciences guides
Explore cover by business activity
Questions about Underwriter Appetite
There is no permanent best market. The answer depends on activity, product, countries, limits, stage, contracts and current appetite - which is why observations are dated rather than labelled.
No. It may reflect that market's appetite or the way the risk was presented. Some risks remain uninsurable or commercially impractical at a point in time, but alternatives can usually be tested.
A specialist insurer may be technically willing to cover a risk but apply a minimum premium disproportionate to a small business's size. The commercially available market is smaller than the technically willing one.
Yes. Capacity, claims, regulation, product trends and underwriting authority all move. An observation from one placement season is a starting point, not a guarantee.
General information only. This page does not take account of your objectives, financial situation or needs and is not legal advice. Cover depends on the insurer, policy wording, limits, excesses, exclusions and information disclosed. Read the relevant policy documents and obtain professional advice before deciding.
Put your life sciences risk in front of the right markets
Tell us what you research, build, test, supply or operate, plus any overseas exposure. We will explain the available terms and exclusions before you decide.